Akili Interactive announced topline data from an open-label study (STARS-ADHD Adjunctive) of AKL-T01 for the treatment of attention deficit hyperactivity disorder in children with or without use of stimulants.
Acute treatment of migraine with ubrogepant, an oral calcitonin gene-related peptide antagonist, was superior to placebo for migraine pain freedom.
The FDA has granted Fast Track designation to AXER-204 (ReNetX Bio) for the potential treatment of chronic spinal cord injury.
The FDA has approved lemborexant for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adult patients.
The Food and Drug Administration (FDA) has approved Ubrelvy (ubrogepant tablets; Allergan), the first oral calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine with or without aura in adults.
The FDA has granted Orphan Drug designation to reldesemtiv (Cytokinetics) for the treatment of amyotrophic lateral sclerosis.
Exposure to certain types of oral antibiotics may be associated with an elevated risk for Parkinson disease.
The FDA has approved the supplemental New Drug Application for riluzole oral suspension to include administration via percutaneous endoscopic gastrostomy (PEG) tubes for the treatment of ALS.
The FDA has granted accelerated approval to Vyondys 53 (golodirsen; Sarepta Therapeutics) injection for the treatment of Duchenne muscular dystrophy.
Inebilizumab is superior to placebo in reducing the risk for a neuromyelitis optica spectrum disorder attack.
